Key result
Emergency coronary artery bypass surgery can be safely performed in patients receiving glycoprotein IIb/IIIa receptor antagonists with little added bleeding risk when appropriate measures are taken.
Why the study?
Can emergency coronary artery bypass surgery be safely performed without excessive bleeding risk in patients recently treated with glycoprotein IIb/IIIa receptor antagonists?
Population
Patients with acute coronary syndrome or undergoing percutaneous coronary intervention who receive…
Design
Review
Authors
Loading...
Supports cautious emergency CABG after GP IIb/IIIa inhibitors with hemostatic measures; hypothesis-generating pending prospective trials.
Can emergency coronary artery bypass surgery be safely performed without excessive bleeding risk in patients recently treated with glycoprotein IIb/IIIa receptor antagonists?
Emergency coronary artery bypass surgery can be safely performed in patients recently treated with GP IIb/IIIa inhibitors provided appropriate hemostatic measures are taken.
Pang et al. (2010) conducted a review in Acute coronary syndrome or undergoing percutaneous coronary intervention requiring emergency coronary artery bypass surgery. Glycoprotein IIb/IIIa receptor antagonists (eptifibatide, tirofiban, abciximab) was evaluated. Emergency coronary artery bypass surgery can be safely performed in patients receiving glycoprotein IIb/IIIa receptor antagonists with little added bleeding risk when appropriate measures are taken.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: